Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03070366 2025-09-02

OMET

Phase 2 Active not recruiting

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04857164 2025-01-28

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Phase 2 Recruiting

150 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06714266 2024-12-03

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05136768 2021-11-29

LM-HNSCC

Phase 2 Unknown

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT02052960 2021-11-02

RESGEX

Phase 2 Completed

240 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Phase 2 Recruiting

53 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04220749 2020-09-04

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Phase 2 Recruiting

68 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01425736 2014-06-03

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

91 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00095641 2013-11-08

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

OMET

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

LM-HNSCC

RESGEX

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer